VivoSeq
Oncology

Lymphoid Neoplasm

34

Pipeline Programs

1

Active Trials

21

Companies Involved

Lymphoid Neoplasm is a moderately active landscape with 34 programs across 21 companies. The most active players are Sumitomo Pharma America, Inc., Biogen, Quince Therapeutics S.p.A.. 17 therapies are approved.

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

7/100

Completion Rate

50/100

Attrition Rate

33/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

79%

Small molecule

27 of 34 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody39%Antibody–drug conjugate13%Protein / enzyme13%Peptide13%Cell therapy13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Trial Status

3

clinical trials

Active, not recruiting1 · 33%
Completed1 · 33%
Terminated1 · 33%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)